Indeed, the patient benefit of treatment with EGFR inhibitors in EGFR-mutated lung adenocarcinoma (LUAD) is well established.7 Unfortunately, attempts to inhibit EGFR signaling in GBM have not yet proven to be beneficial.8,9. The gene discussed is EGFR; the disease is glioblastoma.